Condition: Solid Tumors · Sponsor: Quanta Therapeutics
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
This description comes directly from the study's public registry record.
Quanta Therapeutics Clinical Trials · 415-599-3892 · clinicaltrials@quantatx.com
Always discuss trial participation with your own doctor first.
| UCLA Hematology/Oncology | Los Angeles, California, United States | Recruiting |
| Sarah Cannon Research Institute (SCRI) | Denver, Colorado, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Recruiting |
| SCRI- Nashville | Nashville, Tennessee, United States | Recruiting |
| MD Anderson | Houston, Texas, United States | Recruiting |
| START San Antonio, LLC | San Antonio, Texas, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06227377